Levels of p-EGFR (Y1068), p-AKT (T308) and VEGFR2 in prostate cancer cells were reduced after Enzalumide combined with CCX771 (a CXCR7 inhibitor) compared with single drug therapy (Luo et al., 2018). The gene discussed is ACKR3; the disease is Familial prostate cancer.